Adams Harkness to Webcast Tanox Presentation - Peanut Allergy Information

Adams Harkness to Webcast Tanox Presentation

Publish date:
Social count:


Harkness to Webcast Tanox Presentation

HOUSTON, Aug. 2 /PRNewswire-FirstCall/ -- Tanox, Inc. (Nasdaq: TNOX) announced today that Greg Guidroz, Vice President of Finance, and Ashraf Hanna, Vice President of Strategic Planning, will speak at the Adams Harkness 24th Annual Summer Seminar in Boston, Massachusetts at 11:00 a.m. EDT on Thursday, August 5, 2004. Dr. Hanna and Mr. Guidroz will provide an overview of Tanox's business and review corporate objectives for 2004. A live webcast of the presentation may be accessed on Tanox's corporate website at [url=""][/url] . An archived version of the webcast will be available on the website through September 2, 2004.

About Tanox Tanox, Inc. is a biopharmaceutical company with demonstrated expertise in monoclonal antibody technology. The Company is engaged in the discovery and development of therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation, diseases affecting the human immune system and infectious diseases. In June 2003, the FDA approved Xolair(R) (omalizumab) For Subcutaneous Use for treatment of adults and adolescents (12 years of age and above) with moderate- to-severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair, Tanox's first approved drug, is an antiimmunoglobulin E, or anti-IgE, antibody that was developed under a collaboration agreement among Genentech, Inc., Novartis Pharma AG and Tanox. This release and other information about Tanox, Inc. can be found on the World Wide Web at [url=""][/url] .

SOURCE Tanox, Inc. Web Site: [url=""][/url]